Bridgebio products
WebApr 8, 2024 · BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Rating) CFO Brian C. Stephenson sold 55,500 shares of the company's stock in a transaction dated Wednesday, April 5th. The shares were sold at an average price of $15.45, for a total transaction of $857,475.00. Following the transaction, the chief financial officer now directly owns … WebBridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers.
Bridgebio products
Did you know?
WebMar 23, 2024 · BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic ... WebJan 29, 2024 · An emerging model in Pharmaceutical & Medical Products could disrupt the R&D landscape and open up new ways to invest, motivate teams, and shape the innovation pipeline ... That portfolio model is being pioneered by companies such as BridgeBio and Roivant Sciences. Each has a central management team with a distinctive skill set and a ...
WebApr 11, 2024 · PALO ALTO, Calif., April 11, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. BBIO (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 7, 2024, the compensation committee of BridgeBio’s board of directors granted 11 new … WebApr 6, 2024 · As of April 6, 2024, the average one-year price target for BridgeBio Pharma is $26.78. The forecasts range from a low of $18.18 to a high of $33.60. The average price …
WebMar 22, 2024 · BridgeBio has two approved products in its portfolio, Nulibry (for molybdenum cofactor deficiency Type A) and Truseltiq (for bile duct cancer), which were approved in 2024. The company is yet to ...
WebOct 12, 2024 · BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients …
WebMar 24, 2024 · BridgeBio has 2 employees at their 1 location and $77.65 m in annual revenue in FY 2024. See insights on BridgeBio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Advanced. Products. Solutions. Partners. Resources. Company. Toggle menu. organizational needs analysisWebApr 13, 2024 · Nell’ultimo trimestre Nuvei undefined ha ottenuto le seguenti raccomandazioni degli analisti: Negli ultimi tre mesi, 10 analisti hanno fornito target price a 12 mesi su Nuvei. La società ha un prezzo target medio di 57,90 dollari, con un massimo di 93 dollari e un minimo di 45 dollari. Di seguito è riportato un riepilogo delle valutazioni ... how to use mr hobby mark setterWebApr 12, 2024 · 7 Wall Street analysts have issued 1 year target prices for BridgeBio Pharma's stock. Their BBIO share price forecasts range from $18.00 to $29.00. On average, they predict the company's stock price to reach $23.33 in the next year. This suggests a possible upside of 40.7% from the stock's current price. View analysts price targets for … organizational models in higher educationWeb© 2024 BridgeBio Inc. For Investors careers terms of use privacy policy cookies notice. 3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 650-391-9740 … organizational name changeWebMar 17, 2024 · BridgeBio was selected to share an oral presentation and posters on its ongoing Phase 2 trial with 15-month results, including the preliminary design of its pivotal Phase 3 study in patients with ... organizational names for strategyWebAs of April 6, 2024, the average one-year price target for BridgeBio Pharma is $26.78. The forecasts range from a low of $18.18 to a high of $33.60. The average price target … organizational models in businessWebFeb 24, 2024 · Over the past year, the Company repurchased $150.0 million in BridgeBio common stock under its 2024 Share Repurchase Program and $50.0 million in BridgeBio common stock in conjunction with the issuance of its 2029 convertible notes, prepaid in full $124.1 million of term loans, paid $61.3 million for capped call options related to the … organizational needs assessment paper